FDA Removes Clinical Hold, Allowing MAGNITUDE Trial to Resume for Nex-z in ATTR-CM
Intellia Therapeutics (NASDAQ:NTLA) received a significant boost after the U.S. Food and Drug Administration (FDA) lifted its clinical hold on the MAGNITUDE Phase 3 trial for nexiguran ziclumeran (nex-z) targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This decision enables Intellia to resume its work investigating if a single-dose gene editing treatment can permanently alter the course of this serious disease.
Heightened Safety Protocols Introduced Following Previous Hold in 2025
The FDA’s hold, initiated in late October 2025, came after a patient in the MAGNITUDE trial experienced severe (Grade 4) liver transaminase elevations and increased bilirubin. In response, Intellia and the FDA have aligned on strengthened measures designed to protect patients—a step essential in late-stage gene therapy development.
Key safety enhancements include:
- Frequent liver monitoring immediately post-infusion
- Clear guidance for rapid steroid use if liver transaminase elevations occur
- Stricter trial entry criteria to exclude patients with certain liver issues, recent serious cardiovascular events, or low ejection fraction (<25%)
Pivotal MAGNITUDE and MAGNITUDE-2 Trials Target Transformative Potential
With regulatory hurdles cleared, enrollment for MAGNITUDE—expected to include approximately 1,200 ATTR-CM patients—will proceed. Patients are randomized 2:1 to receive a single 55 mg infusion of nex-z or placebo. The primary endpoint centers on cardiovascular outcomes, including mortality, providing a direct readout of real clinical benefit.
Meanwhile, the smaller MAGNITUDE-2 study targets roughly 60 patients with hereditary ATTR and polyneuropathy (ATTRv-PN), with endpoints tracking neuropathy impairment and serum TTR levels—measures relevant to both disease activity and treatment response.
| Study | Population | Design | Primary Endpoint | Intervention |
|---|---|---|---|---|
| MAGNITUDE | ~1,200 ATTR-CM | Randomized, double-blind, 2:1 (nex-z vs. placebo) | Composite cardiovascular events (incl. mortality) | Single 55 mg infusion |
| MAGNITUDE-2 | ~60 ATTRv-PN | Randomized, double-blind, 1:1 (nex-z vs. placebo) | Neuropathy score, serum TTR change | Single 55 mg infusion |
Nex-z’s Potential: One-Time CRISPR Therapy Receives Multiple Regulatory Designations
Nex-z leverages Nobel-winning CRISPR/Cas9 technology, aiming to permanently silence the TTR gene and halt disease progression after just a single dose. Early phase studies have already demonstrated deep and durable TTR reduction in treated patients.
Reflecting the unmet need and innovation, nex-z has received Orphan Drug and RMAT (Regenerative Medicine Advanced Therapy) designations from the FDA and an Orphan Drug Designation from the European Commission. The therapy’s development involves a notable collaboration between Intellia and Regeneron Pharmaceuticals.
What’s Next: Investor Takeaways as FDA Clearance Presses the Accelerator
Today’s FDA clearance is a crucial signal that Intellia’s approach remains on track, albeit with enhanced safety guardrails. Investors will be watching enrollment rates and upcoming data readouts for both MAGNITUDE and MAGNITUDE-2, as success could position nex-z to become the first-ever one-and-done gene editing treatment for ATTR amyloidosis—including both cardiac and neurological forms.
While there are still clinical and regulatory risks, Intellia’s progress represents a milestone for the expanding field of CRISPR-based therapeutics. For those tracking future therapies, this is a company and a pipeline worth keeping on the radar as the clinical story unfolds.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI